IMVT
Price
$16.39
Change
+$0.64 (+4.06%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
2.69B
41 days until earnings call
OCUL
Price
$9.46
Change
+$0.27 (+2.94%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
1.46B
46 days until earnings call
Interact to see
Advertisement

IMVT vs OCUL

Header iconIMVT vs OCUL Comparison
Open Charts IMVT vs OCULBanner chart's image
Immunovant
Price$16.39
Change+$0.64 (+4.06%)
Volume$35.19K
Capitalization2.69B
Ocular Therapeutix
Price$9.46
Change+$0.27 (+2.94%)
Volume$86.28K
Capitalization1.46B
IMVT vs OCUL Comparison Chart in %
Loading...
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMVT vs. OCUL commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMVT is a Buy and OCUL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (IMVT: $15.75 vs. OCUL: $9.19)
Brand notoriety: IMVT and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMVT: 83% vs. OCUL: 141%
Market capitalization -- IMVT: $2.69B vs. OCUL: $1.46B
IMVT [@Biotechnology] is valued at $2.69B. OCUL’s [@Biotechnology] market capitalization is $1.46B. The market cap for tickers in the [@Biotechnology] industry ranges from $312.97B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMVT’s FA Score shows that 0 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • IMVT’s FA Score: 0 green, 5 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, both IMVT and OCUL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMVT’s TA Score shows that 5 TA indicator(s) are bullish while OCUL’s TA Score has 7 bullish TA indicator(s).

  • IMVT’s TA Score: 5 bullish, 5 bearish.
  • OCUL’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, OCUL is a better buy in the short-term than IMVT.

Price Growth

IMVT (@Biotechnology) experienced а -0.69% price change this week, while OCUL (@Biotechnology) price change was +10.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.00%. For the same industry, the average monthly price growth was +32.55%, and the average quarterly price growth was +15.13%.

Reported Earning Dates

IMVT is expected to report earnings on Aug 06, 2025.

OCUL is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+2.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMVT($2.69B) has a higher market cap than OCUL($1.46B). OCUL YTD gains are higher at: 7.611 vs. IMVT (-36.415). OCUL has higher annual earnings (EBITDA): -176.35M vs. IMVT (-437.78M). IMVT has more cash in the bank: 714M vs. OCUL (350M). IMVT has less debt than OCUL: IMVT (98K) vs OCUL (76.2M). OCUL has higher revenues than IMVT: OCUL (59.6M) vs IMVT (0).
IMVTOCULIMVT / OCUL
Capitalization2.69B1.46B184%
EBITDA-437.78M-176.35M248%
Gain YTD-36.4157.611-478%
P/E RatioN/AN/A-
Revenue059.6M-
Total Cash714M350M204%
Total Debt98K76.2M0%
FUNDAMENTALS RATINGS
IMVT vs OCUL: Fundamental Ratings
IMVT
OCUL
OUTLOOK RATING
1..100
5914
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
54
Fair valued
PROFIT vs RISK RATING
1..100
10088
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
6340
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
2750

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMVT's Valuation (43) in the null industry is in the same range as OCUL (54) in the Pharmaceuticals Other industry. This means that IMVT’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Profit vs Risk Rating (88) in the Pharmaceuticals Other industry is in the same range as IMVT (100) in the null industry. This means that OCUL’s stock grew similarly to IMVT’s over the last 12 months.

OCUL's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as IMVT (97) in the null industry. This means that OCUL’s stock grew similarly to IMVT’s over the last 12 months.

OCUL's Price Growth Rating (40) in the Pharmaceuticals Other industry is in the same range as IMVT (63) in the null industry. This means that OCUL’s stock grew similarly to IMVT’s over the last 12 months.

OCUL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as IMVT (100) in the null industry. This means that OCUL’s stock grew similarly to IMVT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMVTOCUL
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 21 days ago
77%
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 7 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DVZRX69.46N/A
N/A
Macquarie Small Cap Value R6
LICOX17.46N/A
N/A
Lord Abbett International Equity F3
ARMIX12.16N/A
N/A
ARGA Emerging Markets Value Instl
MAEFX24.11N/A
N/A
BlackRock International Select Eq Instl
FCIAX61.58-0.02
-0.03%
American Funds Invmt Co of Amer 529-F-2

IMVT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
-1.56%
ROIV - IMVT
61%
Loosely correlated
-1.21%
OCUL - IMVT
51%
Loosely correlated
+1.10%
XENE - IMVT
49%
Loosely correlated
-1.27%
RVMD - IMVT
49%
Loosely correlated
-4.05%
CGON - IMVT
48%
Loosely correlated
+1.01%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+1.10%
EYPT - OCUL
56%
Loosely correlated
+14.81%
DNLI - OCUL
55%
Loosely correlated
+0.35%
RNA - OCUL
51%
Loosely correlated
+0.10%
IMVT - OCUL
49%
Loosely correlated
-1.56%
RVMD - OCUL
49%
Loosely correlated
-4.05%
More